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Abstract 
 
Diabetes and diabetic nephropathy (DN) are complex diseases reflecting a complex 
interplay between genetic and non-genetic factors. The insulin-like growth factor (IGF) - 
IGF binding protein (IGFBP) axis plays an important role in the development of diabetes 
and DN. Recent reports have demonstrated that genetic polymorphisms in this axis are 
associated with diabetes and DN. However, the information of epigenetic study is very 
limited. In this study, we selected four genes from this axis including IGF1, IGF2, 
IGFBP1 and IGF2BP2 to evaluate their genetic and epigenetic associations with 
diabetes and DN. In parallel, we analyzed the serum protein levels.  
 
SNP rs35767 in the IGF1 gene promoter region has been reported to be associated with 
insulin resistance and circulating IGF-I levels. In Study I, we analyzed IGF1 DNA 
methylation levels at CpG sites in the promoter region including this SNP and measured 
serum IGF-I concentration in Swedish subjects with normal glucose tolerance (NGT) or 
type 2 diabetes (T2D). Data suggested that increased DNA methylation in the gene 
promoter and decreased circulating IGF-I levels are associated with T2D. 
 
IGFBP-1 is produced in liver and mainly regulated by insulin. Clinical   observations  
have   demonstrated   that   high   levels   of   circulating   IGFBP-1   are   associated   with   T1D,  
while  low  serum  levels  are  associated  with  the  risk  of  T2D.  There is a CpG island at the 
promoter   and   5’-untranlated   region   (5’-UTR) of the IGFBP1 gene. We analyzed 
IGFBP1  DNA  methylation  levels  in  Swedish  T2D  patients  (Study  II)  and  T1D  patients  
with  or  without  DN  (Study  III). Results demonstrated that IGFBP1 DNA methylation 
levels were decreased in T1D patients but increased in T2D patients in comparison with 
NGT subjects. Furthermore, decreased and increased IGFBP-1 serum levels were 
respectively associated with T2D and T1D.  
 
The IGF2BP2 gene is located on chromosome 3q27.2 within a region linked to diabetes 
and DN. The protein encoded IGF2BP2 binds to 5'-UTR of the imprinting IGF2 gene, 
which is located on chromosome 11p15.5. In Study IV, we genotyped SNPs rs10770125 
(A/G) and rs4402960 (G/T) in the IGF2 and IGF2BP2 genes respectively. Diabetes 
patients with or without DN and NGT subjects from GoKinD, Czech and Swedish 
populations were enrolled in this study. Data showed that the IGF2BP2 polymorphism 
rs4402960 was associated with T2D. This IGF2BP2 polymorphism and rs10770125 in 
the IGF2 gene were found to be associated with DN in male T1D patients.  
 
In conclusion, our studies provide evidence that the IGF1, IGF2, IGFBP1 and IGF2BP2 
genes have genetic and epigenetic effects in diabetes and DN. To better understand the 
importance of our findings, further investigations of tissue specific DNA methylation 
levels and their impacts on translated proteins are needed. 
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